The goal of this activity is for learners to be better able to understand the need for further comprehensive cardio-renal-metabolic risk control and weight loss beyond presently available therapies and be aware of emerging incretin-based therapies currently in clinical development.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1001235
- Start Date: 2024-06-27 05:00:00
- End Date: 2024-06-27 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Novo Nordisk (Any division) - Amount: 136033.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Cardiovascular Disease, Endocrinology, Diabetes, and Metabolism, Internal Medicine
Subscribe
Login
0 Comments
Oldest